Monoclonal antibody · Inhibitor of complement C5 (C5) · developed by Regeneron Pharmaceuticals
Pozelimab is a human IgG4 monoclonal antibody that binds the terminal complement protein C5, blocking its cleavage into C5a and C5b and thereby preventing membrane-attack complex formation.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Dec 4, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06541704 | Phase 3 | Age-related Macular Degeneration (AMD) | Recruiting | REGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Paroxysmal Nocturnal Hemoglobinuria
Updated Nov 8, 2026. Something wrong or missing? Report it on the REGN page.
See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
REGN catalysts and pipeline →